Hereditary Sensory Neuropathy Serine Trial

计划入组 50 人 · 首次发布于 2023 年 11 月 2 日

Impact of Sensory, Motor and Vestibular Deficit on the Postural Stability of CMT Patients

计划入组 60 人 · 首次发布于 2024 年 5 月 23 日

L-Serine Supplementation in Hereditary Sensory Neuropathy Type 1

计划入组 18 人 · 首次发布于 2012 年 11 月 27 日

AAV2 smCBA based ND4 gene therapy (Leber hereditary optic neuropathy)

Idebenone(Raxone)

C₁₉H₃₀O₅ · Rx

RNA actuator therapeutic for hereditary angioedema(CAMP4 Therapeutics)

Biora Therapeutics

United States

NeuroBo Pharmaceuticals

United States

Astria Therapeutics Inc

United States

Wearable Tech Shows Promise in Monitoring CMT Disease Progression for Clinical Trials

Applied Therapeutics Faces Regulatory Setback as FDA Meeting Fails to Establish Govorestat Approval Pathway

GenSight Biologics Successfully Transfers LUMEVOQ Manufacturing to Catalent for LHON Gene Therapy